GenSight Biologics Reports Cash Position and Revenue from Early Access Program as of March 31, 2026

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position and the revenues from its Named Patient Early Access Program as of March 31, 2026. Cash position as of March 31, 2026 GenSight Biologics’ cash and cash equivalents totaled €3.2 million